BioXcel Therapeutics (BTAI) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of BioXcel Therapeutics (NASDAQ:BTAI) from a hold rating to a buy rating in a report released on Thursday, April 11th, ValuEngine reports.

Several other equities analysts have also recently commented on BTAI. HC Wainwright reiterated a buy rating and set a $25.00 target price on shares of BioXcel Therapeutics in a research note on Wednesday, December 12th. Zacks Investment Research cut shares of BioXcel Therapeutics from a hold rating to a sell rating in a research note on Thursday, December 27th. Finally, Canaccord Genuity set a $21.00 target price on shares of BioXcel Therapeutics and gave the company a buy rating in a research note on Friday, March 8th.

BTAI stock traded up $0.07 during trading hours on Thursday, hitting $10.43. The company’s stock had a trading volume of 41,926 shares, compared to its average volume of 31,801. The company has a market capitalization of $163.40 million, a price-to-earnings ratio of -7.90 and a beta of 4.10. BioXcel Therapeutics has a 12 month low of $2.41 and a 12 month high of $14.79.

BioXcel Therapeutics (NASDAQ:BTAI) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.47) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.13). As a group, sell-side analysts expect that BioXcel Therapeutics will post -2.21 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in BioXcel Therapeutics stock. Creative Planning bought a new position in BioXcel Therapeutics Inc (NASDAQ:BTAI) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 30,550 shares of the company’s stock, valued at approximately $302,000. Creative Planning owned about 0.20% of BioXcel Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 15.46% of the company’s stock.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

Featured Story: Trading based on a resistance level

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.